JC

James Calloway

Financial Reporter

James Calloway is a financial reporter at StockTi covering corporate earnings, regulatory policy, and market-moving events. A former business journalist with Reuters, James has covered financial markets for over eight years across New York and Washington. He specializes in breaking down earnings reports, SEC filings, and policy decisions that affect publicly traded companies and investor portfolios.

Earnings, Regulation 3,625 articles

Articles by James Calloway

Clorox Stock Climbs on FY2027 Sales Outlook, Yet Core Growth Stays Flat
Earnings

Clorox Stock Climbs on FY2027 Sales Outlook, Yet Core Growth Stays Flat

Clorox (CLX) issued a fiscal 2027 sales growth forecast of 13-14%, beating consensus, but underlying organic growth is under 0.5% as acquisitions and ERP timing drive most of the gain. EPS guidance trails estimates.

CLX PG ECL CL
Powell Industries Shares Slide on Record Backlog Execution Concerns
Earnings

Powell Industries Shares Slide on Record Backlog Execution Concerns

Powell Industries shares dropped 13.8% in after-hours trading as record backlog raises delivery concerns, despite Q3 revenue and EPS beating estimates.

POWL ETN HUBB VRT
Whirlpool Faces Steep H2 Cash Hurdle After EBIT Plunge
Earnings

Whirlpool Faces Steep H2 Cash Hurdle After EBIT Plunge

Whirlpool (WHR) needs over $1.4B in H2 free cash flow after Q2 EBIT dropped 69%. Shares slipped 1.7% in after-hours trading despite a 4.6% gain.

WHR
Sterling Infrastructure Q2 Revenue Soars 90%, But Margin Outlook Weighs on Shares
Earnings

Sterling Infrastructure Q2 Revenue Soars 90%, But Margin Outlook Weighs on Shares

Sterling Infrastructure's Q2 revenue jumped 90%, but after-hours shares dropped 4.7% as the 2026 margin outlook implied a tighter incremental EBITDA margin.

STRL ECG
Vertex Raises Outlook as CF Dominates, Non-CF Push Faces Steep Climb
Earnings

Vertex Raises Outlook as CF Dominates, Non-CF Push Faces Steep Climb

Vertex Pharmaceuticals raised its 2026 outlook after strong Q2, but non-CF drugs Casgevy and Journavx face a 53% H2 growth hurdle.

VRTX CRNX REGN GILD
Ford Shares Stall Post-Earnings Despite Raised 2026 Profit Forecast
Earnings

Ford Shares Stall Post-Earnings Despite Raised 2026 Profit Forecast

Ford's stock fell 1.7% to $14.43 despite a 10.5% midpoint increase in its 2026 adjusted EBIT guidance. The automaker also faces a production halt in Romania due to electricity supply issues.

F GM STLA
ON Semiconductor Q2 Beats Estimates, Cash Flow Surge Raises Questions
Earnings

ON Semiconductor Q2 Beats Estimates, Cash Flow Surge Raises Questions

ON Semiconductor shares gained after Q2 results beat expectations, with revenue and EPS surpassing consensus. However, the company's cash flow growth was aided by working capital changes, raising sustainability concerns.

ON SYNA
Celsius Holdings Faces Pre-Earnings Slide as Investors Eye Core Growth
Earnings

Celsius Holdings Faces Pre-Earnings Slide as Investors Eye Core Growth

Celsius Holdings (CELH) shares declined 3.4% to $28.23 ahead of Q2 earnings, with investors focused on core brand growth and margin trends. Analysts expect revenue of $887.7 million.

CELH MNST PEP
Hims & Hers Stock Rebounds 11% Ahead of Q2 Earnings Test
Earnings

Hims & Hers Stock Rebounds 11% Ahead of Q2 Earnings Test

Hims & Hers shares surged 11% before earnings, erasing FTC-related losses. The focus now shifts to margin recovery and Eucalyptus integration.

HIMS NVO JEF
Opendoor Shares Surge Ahead of Q2 Report; Margin Outlook in Focus
Earnings

Opendoor Shares Surge Ahead of Q2 Report; Margin Outlook in Focus

Opendoor shares climbed 4.5% ahead of Q2 results, with revenue expected near $900M. Investors focus on contribution margin and adjusted EBITDA as the company scales purchases.

OPEN OPAD
Blue Owl Capital Surges 8% as Real Assets Drive Q2 Fundraising
Earnings

Blue Owl Capital Surges 8% as Real Assets Drive Q2 Fundraising

Blue Owl Capital (OWL) rose 8% after Q2 fundraising got a boost from real assets, which captured 59% of equity inflows. The firm sees potential $380M in annual fees from undeployed capital.

OWL ARES BX KKR APO OBDC
Xylem Stock Rebounds as $850M Dow Contract Drives Order Surge
Earnings

Xylem Stock Rebounds as $850M Dow Contract Drives Order Surge

Xylem shares rose 1.8% after a $850M Dow contract boosted orders by 42%, but the company trimmed its revenue outlook while raising EPS guidance.

XYL DOW VLTO PNR WTS BMI